{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:49:56Z","timestamp":1792273796007,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,25]]},"DOI":"10.7759\/cureus.67776","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:14:48Z","timestamp":1724652888000},"source":"Crossref","is-referenced-by-count":2,"title":["Efavirenz: New Hope in Cancer Therapy"],"prefix":"10.7759","author":[{"given":"Varshitha Dheep","family":"Elango","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma Maheshwari","family":"Mugundan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajanandh","family":"MG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Breast cancer. (2024). Accessed. March 13, 2024: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref2","unstructured":"Key statistics for breast cancer. (2024). Accessed. March 15, 2024: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/how-common-is-breast-cancer.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041320","article-title":"Targeted therapy and mechanisms of drug resistance in breast cancer","volume":"15","author":"Kinnel B","year":"2023","unstructured":"Kinnel B, Singh SK, Oprea-Ilies G, Singh R. Targeted therapy and mechanisms of drug resistance in breast cancer. Cancers (Basel). 2023, 15:10.3390\/cancers15041320","journal-title":"Cancers (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/35057062","article-title":"Initial sequencing and analysis of the human genome","volume":"409","author":"Lander ES","year":"2001","unstructured":"Lander ES, Linton LM, Birren B, et al.. Initial sequencing and analysis of the human genome. Nature. 2001, 409:860-921. 10.1038\/35057062","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-082509-141802","article-title":"LINE-1 elements in structural variation and disease","volume":"12","author":"Beck CR","year":"2011","unstructured":"Beck CR, Garcia-Perez JL, Badge RM, Moran JV. LINE-1 elements in structural variation and disease. Annu Rev Genomics Hum Genet. 2011, 12:187-215. 10.1146\/annurev-genom-082509-141802","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2741\/4644","article-title":"LINE-1 as a therapeutic target for castration-resistant prostate cancer","volume":"23","author":"Houede N","year":"2018","unstructured":"Houede N, Piazza PV, Pourquier P. LINE-1 as a therapeutic target for castration-resistant prostate cancer. Front Biosci (Landmark Ed). 2018, 23:1292-309. 10.2741\/4644","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2812-7","article-title":"Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells","volume":"143","author":"Patnala R","year":"2014","unstructured":"Patnala R, Lee SH, Dahlstrom JE, Ohms S, Chen L, Dheen ST, Rangasamy D. Inhibition of LINE-1 retrotransposon-encoded reverse transcriptase modulates the expression of cell differentiation genes in breast cancer cells. Breast Cancer Res Treat. 2014, 143:239-53. 10.1007\/s10549-013-2812-7","journal-title":"Breast Cancer Res Treat"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2091-12-18","article-title":"Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition","volume":"12","author":"Dai L","year":"2011","unstructured":"Dai L, Huang Q, Boeke JD. Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition. BMC Biochem. 2011, 12:18. 10.1186\/1471-2091-12-18","journal-title":"BMC Biochem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1822","article-title":"Silencing of LINE-1 retrotransposons contributes to variation in small noncoding RNA expression in human cancer cells","volume":"5","author":"Ohms S","year":"2014","unstructured":"Ohms S, Rangasamy D. Silencing of LINE-1 retrotransposons contributes to variation in small noncoding RNA expression in human cancer cells. Oncotarget. 2014, 5:4103-17. 10.18632\/oncotarget.1822","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208562","article-title":"Inhibition of endogenous reverse transcriptase antagonizes human tumor growth","volume":"24","author":"Sciamanna I","year":"2005","unstructured":"Sciamanna I, Landriscina M, Pittoggi C, et al.. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene. 2005, 24:3923-31. 10.1038\/sj.onc.1208562","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1566524015666150831130827","article-title":"Activation of LINE-1 retrotransposon increases the risk of epithelial-mesenchymal transition and metastasis in epithelial cancer","volume":"15","author":"Rangasamy D","year":"2015","unstructured":"Rangasamy D, Lenka N, Ohms S, Dahlstrom JE, Blackburn AC, Board PG. Activation of LINE-1 retrotransposon increases the risk of epithelial-mesenchymal transition and metastasis in epithelial cancer. Curr Mol Med. 2015, 15:588-97. 10.2174\/1566524015666150831130827","journal-title":"Curr Mol Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02424-5","article-title":"Efavirenz as a potential drug for the treatment of triple-negative breast cancers","volume":"23","author":"Chiou PT","year":"2021","unstructured":"Chiou PT, Ohms S, Board PG, Dahlstrom JE, Rangasamy D, Casarotto MG. Efavirenz as a potential drug for the treatment of triple-negative breast cancers. Clin Transl Oncol. 2021, 23:353-63. 10.1007\/s12094-020-02424-5","journal-title":"Clin Transl Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0317-9","article-title":"When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance","volume":"38","author":"Kuo CY","year":"2018","unstructured":"Kuo CY, Ann DK. When fats commit crimes: fatty acid metabolism, cancer stemness and therapeutic resistance. Cancer Commun (Lond). 2018, 38:47. 10.1186\/s40880-018-0317-9","journal-title":"Cancer Commun (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23647","article-title":"Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells","volume":"52","author":"Blas-Garc\u00eda A","year":"2010","unstructured":"Blas-Garc\u00eda A, Apostolova N, Ballesteros D, et al.. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010, 52:115-25. 10.1002\/hep.23647","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16869","article-title":"ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"8","author":"Liu D","year":"2017","unstructured":"Liu D, Wu N, Sun H, et al.. ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP. Oncotarget. 2017, 8:58292-303. 10.18632\/oncotarget.16869","journal-title":"Oncotarget"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00866.x","article-title":"Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells","volume":"160","author":"Apostolova N","year":"2010","unstructured":"Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV. Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol. 2010, 160:2069-84. 10.1111\/j.1476-5381.2010.00866.x","journal-title":"Br J Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.7523","article-title":"Cytotoxic effect of efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation","volume":"15","author":"Hecht M","year":"2018","unstructured":"Hecht M, Harrer T, K\u00f6rber V, et al.. Cytotoxic effect of efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation. Oncol Lett. 2018, 15:1728-36. 10.3892\/ol.2017.7523","journal-title":"Oncol Lett"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gde.2016.04.003","article-title":"Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches","volume":"38","author":"Berridge MV","year":"2016","unstructured":"Berridge MV, McConnell MJ, Grasso C, Bajzikova M, Kovarova J, Neuzil J. Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches. Curr Opin Genet Dev. 2016, 38:75-82. 10.1016\/j.gde.2016.04.003","journal-title":"Curr Opin Genet Dev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2022.2161803","article-title":"Combination of metformin\/efavirenz\/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification","volume":"24","author":"Kang BG","year":"2023","unstructured":"Kang BG, Shende M, Inci G, et al.. Combination of metformin\/efavirenz\/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification. Cancer Biol Ther. 2023, 24:20-32. 10.1080\/15384047.2022.2161803","journal-title":"Cancer Biol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281906-efavirenz-new-hope-in-cancer-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T06:14:55Z","timestamp":1724652895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281906-efavirenz-new-hope-in-cancer-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,25]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.67776","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,25]]}}}